Apyx Medical Corporation (APYX) – What Are Researchers Thinking About This Stock?

Shares of Apyx Medical Corporation (NASDAQ:APYX – Get Free Report) have earned an average rating of “Moderate Buy” from the seven ratings firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $6.20.

Several analysts have commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Apyx Medical in a research note on Monday, September 21st. Maxim Group initiated coverage on Apyx Medical in a research note on Tuesday, September 29th. They set a “buy” rating and a $6.00 price target on the stock.

View Our Latest Stock Analysis on APYX

Institutional Investors Weigh In On Apyx Medical

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Nwam LLC purchased a new position in Apyx Medical during the first quarter worth about $47,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Apyx Medical in the 2nd quarter worth about $62,000. AXQ Capital LP acquired a new stake in Apyx Medical in the 2nd quarter worth about $78,000. HighTower Advisors LLC purchased a new stake in Apyx Medical in the 3rd quarter valued at about $51,000. Finally, Jefferies Financial Group Inc. acquired a new position in shares of Apyx Medical during the 2nd quarter valued at about $110,000. Hedge funds and other institutional investors own 55.33% of the company’s stock.

Apyx Medical Stock Performance

NASDAQ:APYX opened at $2.81 on Monday. The firm has a 50 day simple moving average of $2.72 and a 200-day simple moving average of $3.55. The company has a debt-to-equity ratio of 3.54, a current ratio of 4.95 and a quick ratio of 3.85. The firm has a market cap of $118.37 million, a PE ratio of -14.79 and a beta of 1.47. Apyx Medical has a 1-year low of $2.25 and a 1-year high of $5.08.

Apyx Medical (NASDAQ:APYX – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.05. Apyx Medical had a negative net margin of 14.16% and a negative return on equity of 68.79%. The business had revenue of $14.03 million for the quarter, compared to the consensus estimate of $13.29 million. On average, equities analysts expect that Apyx Medical will post -0.21 EPS for the current year.

About Apyx Medical

(Get Free Report)

Apyx Medical Corporation is a medical technology company focused on advanced energy devices for surgical and aesthetic procedures. Its main product is the Renuvion system, which combines helium plasma with radiofrequency energy for use in procedures covered by applicable regulatory clearances. The company also supplies electrosurgical generators and related products, including through its original equipment manufacturing business. Apyx Medical was formerly known as Bovie Medical Corporation and adopted its current name in 2018.

See Also

Analyst Recommendations for Apyx Medical (NASDAQ:APYX)

Receive News & Ratings for Apyx Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apyx Medical and related companies with MarketBeat.com's FREE daily email newsletter.